Canopy Biosciences, LLC announced Wednesday the acquisition of Core Diagnostics, a leading CLIA-certified provider of biomarker analysis services for biopharmaceutical researchers. With the acquisition of Core Diagnostics, Canopy Biosciences will be able to perform its multi-omic immune profiling services in the highly regulated CLIA environment. In addition to NanoString transcriptional profiling, Core Diagnostics also offers histopathology services including immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH). The acquisition of Core Diagnostics follows the acquisition of Zellkraftwerk, GmbH, which joined Canopy earlier this year. Both acquisitions were made possible by strategic growth investments from Ampersand Capital Partners.
Discovery Life SciencesTM (Discovery) today announced the acquisition of QualTek Molecular Laboratories (QualTek), a renowned provider of immunohistochemistry (IHC) services with CAP/CLIA-accredited and Good Laboratory Practice-(GLP) capable laboratories in California and Pennsylvania, respectively. QualTek’s acquisition significantly augments Discovery’s existing histopathology services and creates a uniquely powerful suite of solutions that include one of the world’s largest commercial biorepositories and biospecimen procurement networks, the HudsonAlpha Discovery sequencing and bioinformatics laboratory, and innovative flow cytometry and cell-based laboratory services.
Capital Partners¨ is pleased to announce that Capital Partners Private Equity Income Fund III, LP, a $600 million committed fund, completed an investment in Allentown, Inc. (“Allentown”) on October 22, 2019 in partnership with John Coiro, second-generation family member, CEO and Chairman, whom will continue to lead the company. Headquartered in Allentown, NJ, Allentown is the dominant innovator and brand-name supplier of animal housing to preclinical in vivo research labs in North America. With more than 40 years of experience in manufacturing lab animal housings, Allentown’s extensive industry knowledge has helped the pharmaceutical industry efficiently develop life-saving drugs as it has improved the supply and design of animal housing systems to include individual self-contained environments. The Company’s dedicated engineering and design team works with customers to design and supply custom animal housing systems that fit the customer’s needs based on capacity, automation preference, monitoring need, and most importantly, improved animal quality of life.
Louisville-based 3DR Laboratories LLC has been acquired by Accumen Inc. Terms of the deal, which closed on Monday, were not disclosed. Phoenix-based Accumen is a health care consulting and services company, while 3DR Laboratories offers radiological imaging post-processing services, according to a news release. In short, 3DR makes 3D images out of 2D radiological scans. The company began the process of seeking a buyer about a year ago, David Ferguson, 3DR’s senior managing director and chairman of its board of directors, said in an interview. He also declined to disclose the purchase price for 3DR. Accumen’s growth strategy is to acquire firms and add them to their portfolio of companies. This is the third acquisition that Accumen made since itself was acquired by Arsenal Capital Partners.
LabCorp¨ (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, has completed its acquisition of the diagnostic clinical laboratory testing business of South Bend Medical Foundation (SBMF), considerably enhancing the scope of local services that LabCorp offers to hospitals, physicians, and patients across Indiana, Michigan, Ohio, and Illinois. In addition, LabCorp and SBMF will collaborate to provide integrated pathology services to customers in the region, providing an optimal combination of SBMF’s professional pathology services and LabCorp’s advanced technical capabilities, in addition to more efficient access to the leading specialty services of LabCorp’s Dianon Pathology and Integrated Oncology laboratories.
Accelerated Enrollment Solutions (AES), a business unit of Pharmaceutical Product Development, LLC (PPD), has acquired the clinical research site business of Bioclinica, expanding AES’ global footprint and solidifying its leadership position in patient access and site conduct. AES services now extend across five continents, 20 countries, over 180 research sites and more than 100 million households. The acquisition extends AES’ reach into new geographies in China, Latin America and Western Europe, augmenting its strong presence in North America, Europe and South Africa. The transaction includes research sites from the merger of Bioclinica and CCBR-SYNARC in 2014. AES also expands its therapeutic area scope within the United States, adding four dedicated research sites in Florida, branded Compass Research, with significant expertise in neuroscience.
GeneCentric Therapeutics, Inc. announced Thursday that it has acquired Select ImmunoGenomics, LLC, a Chapel Hill, NC-based provider of advanced immunogenomic, data analysis and biomarker development services to support the development of immuno-oncology drugs. The acquisition provides the combined company with a comprehensive, integrated set of RNA-based solutions to enhance drug development by identifying the right patients for oncology drugs, improving response rates and durability, and ultimately patient outcomes. Financial terms were not disclosed. Select ImmunoGenomics was founded by two University of North Carolina researchers, Benjamin Vincent, MD, an expert in computational immune-genomics, and Joel Parker, PhD, a genomics and data science expert. The company supported clients at research as well as at diagnostics and drug development organizations.
Caprion Biosciences (“Caprion”) and HistoGeneX announced today they have agreed to combine their respective businesses. The new partnership creates a global leader in immune monitoring, protein characterization, and tissue pathology solutions for immunotherapy and drug development. The combined business will provide a full suite of immune monitoring and biomarker development services, from preclinical through late stage clinical trials and companion diagnostics, to biopharmaceutical organizations globally. The partnership was facilitated by a substantial investment from Arsenal Capital Partners (“Arsenal”), a leading specialized private equity firm that invests in middle-market healthcare and specialty industrials companies. Arsenal is focused on partnering with management teams to build market-leading businesses that make a positive impact on healthcare, and will provide the partnership with significant strategic, operational and financial resources to support future growth initiatives. Caprion has been acquired from GHO Capital, a leading specialist healthcare investment advisor based in London. HistoGeneX was previously in partnership with Waterland Private Equity Investments, a European mid-market private equity investment firm focused on buy and build strategies. The terms of Arsenal’s investment were not disclosed.
COSTAS,Inc. (OTC: CSSI), announces its acquisition of Atlas Nanotech (formerly known as Nano Creaciones SAPI de CV) in an all-stock transaction that marks the Company’s entrance into the multi-billion-dollar global nanomedicine marketplace. The terms of the share exchange agreement include the appointment of new managing officers and a new board of directors, the resignation of COSTA’s current officers and board of directors and the retirement of 12,660,000 shares. The principles of Atlas are receiving 25,000,000 shares of CSSI subject to a lock-up agreement with staggered release of shares over a 2-year period. Atlas Nanotech (FKA Nano Creaciones SAPI de CV) is a Guadalajara based high-tech nanotechnology research and development company focused on the field of nanomedicine. The company patents and licenses nanomedicine developments for worldwide distribution. Atlas is focused on bringing to market state-of-the-art products derived from the latest breakthroughs in nanotechnology as it is applied to the medical field.
Thermo Fisher Scientific, the world leader in serving science, today announced that it has completed the acquisition of HighChem, Ltd., a leading developer of mass spectrometry software based in Bratislava, Slovakia. HighChem software solutions are used to analyze complex data and identify small molecules in pharmaceutical and metabolomics laboratories. HighChem will be integrated into the chromatography and mass spectrometry business within the Analytical Instruments Segment. Terms of the acquisition were not disclosed.
What We Do
Who We Are
How We Work
Who We Help
Get In Touch
Connect With Us
Subscribe to Our Daily Note
We publish a Daily Note that aggregates M&A activity, notable developments, regulatory changes, and conferences we deem to be of interest to our partners. It is a quick afternoon read and an easy way to keep your finger on the pulse of the healthcare space. Please fill in your name and email address below if you wish to subscribe.